Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Study:

A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer

Rationale:

n/a

Purpose:

Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer

Study Status: Recruiting

Recruiting:
Pierre Triozzi, MD triozzp@ccf.org

Condition Intervention Phase
Advanced and/or Metastatic Solid Organ Cancer Drug: VB-111 Phase 1

Verified by Vascular Biogenics Ltd. operating as VBL Therapeutics March, 2012

Sponsored by: Vascular Biogenics Ltd. operating as VBL Therapeutics
Information provided by: Vascular Biogenics Ltd. operating as VBL Therapeutics
ClinicalTrials.gov identifier: NCT00559117

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44129
United States

Pierre Triozzi, Dr.., Principal Investigator
Andrew Brenner, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.